Gerald Burgstaller is a Principal Investigator and Research Group Leader at Helmholtz Munich's Institute of Lung Health and Immunity and Comprehensive Pneumology Center (CPC). His work focuses on developing innovative immunotherapeutic technologies for chronic lung diseases, particularly Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD). Expertise in extracellular matrix (ECM) biology Specializes in AI-driven drug discovery Develops advanced 3D/4D human disease models His research integrates phenotypic screening with deep learning methods to identify novel molecular targets. Recent publications highlight breakthroughs in: RNA delivery systems for lung diseases Multi-rater organoid detection datasets Spatial nanoparticle profiling in lungs Burgstaller leads a multidisciplinary team working on: Extracellular vesicle mechanisms in fibrosis Computational pathology analysis Medicinal chemistry approaches
Hanne Mørck Nielsen is a Professor and Section Head of the Section for Biologics at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen. As Project Leader and Principal Investigator of the Novo Nordisk Foundation-funded Center for Biopharmaceuticals and Biobarriers in Drug Delivery (2017-present), she directs interdisciplinary research focused on overcoming biological barriers for efficient drug delivery of biopharmaceuticals to seriously ill patients. Her educational foundation includes: PhD in Pharmacy (1995-2000) from the Royal Danish School of Pharmacy and Leiden Academic Centre for Drug Research MSc in Pharmacy (1989-1995) from the Royal Danish School of Pharmacy Professor Nielsen's research centers on designing drug delivery systems (DDS) for therapeutic peptides/proteins, antibiotics, and oligonucleotides using carrier peptides, lipids, and biopolymers. She integrates pharmaceutical formulation design with biological matrix interaction studies, emphasizing mucus, epithelia, and biofilm barriers. Her work leverages in vitro and in vivo models to translate findings to human applications, with particular expertise in cell-penetrating peptides and antimicrobial delivery systems. Analysis of her 116 publications (3237 citations, H-index 34) reveals dominant trends in nanoparticle-based delivery across mucosal barriers, pH-responsive conjugates, and advanced characterization of drug-excipient-biological matrix interactions. Recent work focuses on electrospun wound dressings, siRNA hybrid nanoparticles, and mucoadhesion rheology, demonstrating consistent translational emphasis from fundamental mechanisms to therapeutic applications. Her scientific recognition includes: Danish Medicines Agency memberships (2016-2017) AcademiaNet membership (2015) Journal of Pharmaceutical Sciences Editorial Board (2014) Alfred Benzon Foundation Postdoctoral Fellowship (2001-2002) Extensive PhD examination duties (2003-2012) She has supervised seven PhD students on antibiotic formulations, peptide delivery, and lipidated therapeutic peptides, securing major grants from the Novo Nordisk Foundation, Danish Council for Independent Research, and Innovation Fund Denmark. Current projects address saliva-repellent nanofiber systems and quantitative 19F NMR for cellular uptake studies. As leader of the Center for Biopharmaceuticals and Biobarriers in Drug Delivery, she coordinates interdisciplinary teams developing next-generation biopharmaceutical delivery platforms, with recent work highlighted in international conferences including Tartu, Lund, and Lisbon.
Dr. Priti Kumar is an Associate Professor of Infectious Diseases and Microbial Pathogenesis at Yale University School of Medicine. She serves as Director of Graduate Admissions for the BBS Microbiology Track and Director of the Yale Predoctoral Training Program in Virology. Dr. Kumar is also a Chartered Member of the NIH NIAID Study Section on AIDS Discovery And Development Of Therapeutics. Dr. Kumar received her PhD in Immunology from the Indian Institute of Science in 2002, followed by postdoctoral training at Harvard Medical School. She joined Yale University as an Assistant Professor in 2008 and has been advancing innovative research in virology and gene therapy for over 15 years. Her laboratory conducts translational research focused on developing gene therapy and cure-based approaches for RNA viruses including HIV-1, West Nile virus, Japanese encephalitis virus, dengue, and SARS-CoV-2. Key research areas include: Overcoming in vivo biological barriers for therapeutic delivery Development of nucleic acid delivery platforms (siRNA, CRISPRs) Humanized mouse models for HIV research Live-imaging of viral pathogenesis Transvascular delivery of therapeutics to the CNS Analysis of Dr. Kumar's recent publications (2022-2025) reveals a strong focus on HIV therapeutics, SARS-CoV-2 vaccine and treatment development, and innovative approaches to nucleic acid delivery. Her work spans virology, immunology, and translational medicine, with frequent collaborations across Yale departments. As Director of graduate training programs, Dr. Kumar plays a significant role in mentoring the next generation of virologists and immunologists. Her laboratory within the Yale Virology Laboratories provides students with opportunities to work on cutting-edge translational research that bridges basic science and therapeutic development. Dr. Kumar's research has resulted in numerous high-impact publications in journals including Nature, Cell Host and Microbe, PNAS, and Science, demonstrating her significant contributions to the fields of virology and gene therapy.
Dr. Mandar Deepak Muzumdar is an Associate Professor of Genetics and of Internal Medicine (Medical Oncology) at Yale School of Medicine. He serves as a Member of the Yale Cancer Biology Institute, Scientific Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, and Co-Director of both the Pancreas Program and the Training Program in Genetics. Dr. Muzumdar's educational background includes: AB in Biochemical Sciences from Harvard College (2003) MD from Stanford University School of Medicine (2008) Internship and Residency in Internal Medicine at Brigham and Women's Hospital (2009-2010) Fellowship in Medical Oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital (2014) Postdoctoral Research Fellowship at the Koch Institute for Integrative Cancer Research at MIT (2017) His research focuses on understanding the mechanisms by which genetic, environmental, and host factors contribute to cancer initiation, progression, and maintenance. Dr. Muzumdar's laboratory leverages sophisticated genetically-engineered cell and animal models to define the molecular basis for tumor cell and host adaptations that drive tumorigenesis. His work centers on three major projects: targeting KRAS in pancreatic cancer, deciphering the mechanistic link between obesity and pancreatic cancer, and tracing tumor progression in KRAS-driven cancers. The ultimate goal of his research is to identify novel approaches for cancer prevention and treatment. Dr. Muzumdar's publication record shows a strong focus on pancreatic cancer biology, with significant contributions to understanding KRAS signaling, obesity-cancer connections, and tumor progression mechanisms. His most notable publication appeared in Cell (2020) describing an endocrine-exocrine signaling axis that drives obesity-associated pancreatic cancer. His scientific achievements have been recognized with several prestigious awards: Damon Runyon-Rachleff Innovation Award (2021) New Innovator Award (DP2) from NIH Director's Common Fund (2019) AACR NextGen Grant for Transformative Cancer Research (2019) Early Career Award from Cancer Research (2019) Mentored Clinical Scientist Research Career Development Award (K08) from NCI (2016) As an educator and mentor, Dr. Muzumdar advises multiple graduate students, MD/PhD students, and postdoctoral fellows in his lab. He is committed to training the next generation of scientists and clinicians, integrating research, education, and clinical care to make a greater impact on cancer patient care. His lab provides opportunities for trainees to work with cutting-edge models of pancreatic and lung cancers, with emphasis on translational applications. Dr. Muzumdar directs the Muzumdar Lab, which opened in late 2017 and focuses on pancreatic cancer research using genetically-engineered mouse models that closely recapitulate human disease. The lab investigates how gene mutations interact with environmental factors like obesity to drive cancer progression, with the goal of identifying new strategies for cancer prevention and therapy.
Yuri Mackeyev, PhD is an Assistant Professor at UTHealth Houston, where he works in Dr. Krishnan's research group. His academic journey began with a PhD in Physical Chemistry from Lomonosov's Moscow State University, focusing on fluorinated [60]fullerenes. Before entering academia, he worked as a high school chemistry teacher from 1985 and received six George Soros's Open Society Foundation teaching awards (1996-2001). In 2003, he joined Prof. L.J. Wilson's lab at Rice University to research water-soluble [60]fullerene derivatives and functionalized carbon nanotubes for healthcare applications. Dr. Mackeyev's research occupies an interdisciplinary space between organic chemistry, nanomaterials chemistry, and clinical cancer research. His primary focus is on applications of gold nanoparticles for tissue radiosensitization, imaging, and image-guided cancer therapies. Another significant research direction involves planning and conducting the synthesis of custom [60]fullerene conjugates with anticancer drugs to define better therapeutic targets at the molecular level within cancer cells and tumor vasculature. His work has resulted in over 20 publications in the past decade, primarily focused on medical applications of nanomaterials including gold nanoparticles, carbon nanotubes, graphene nanoribbons, [60]fullerene, and fluorescently-tagged polymeric composites. Analysis of Dr. Mackeyev's recent publications reveals a consistent focus on enhancing cancer treatment through nanotechnology, particularly in improving radiation therapy outcomes. His work spans from fundamental nanomaterial synthesis to preclinical testing in cancer models, with a strong emphasis on translational potential. Key themes include targeted nanoparticle delivery systems, multimodal theranostic approaches, and understanding the mechanisms by which nanomaterials interact with biological systems to enhance cancer therapies. Six George Soros's Open Society Foundation annual awards for teaching (1996-2001) Dr. Mackeyev's research program involves collaborations across disciplines, working with clinicians, physicists, and other scientists to develop innovative cancer treatments. His work in Dr. Krishnan's group at UTHealth Houston represents a significant contribution to the growing field of nanomedicine for cancer therapy, with potential to improve patient outcomes through more effective and targeted treatments.
Dr. Scott D. Olson is an Associate Professor at the University of Texas Health Science Center in the Department of Pediatric Surgery, where he has been conducting research since September 2011. His academic journey includes a BS in Biochemistry from Texas Christian University, a PhD in Molecular and Cellular Biology from Tulane University, and postdoctoral training in the Stem Cell Program at University of California at Davis Health System. Dr. Olson's research centers on mesenchymal stem cells (MSCs) and their therapeutic applications, particularly for Traumatic Brain Injury (TBI). His work explores how MSCs can immunomodulate and restore homeostasis, with a focus on their impressive ability to control immune system activation in inflammatory conditions. His laboratory conducts comparative studies of different MSC preparations to identify optimal therapeutic candidates and investigates MSC interactions with immune cells, particularly monocytes and macrophages. Dr. Olson's research program has evolved from studying MSC applications for Huntington's Disease at UC Davis to focusing on TBI treatment at UTHealth. His work demonstrates a consistent theme of leveraging MSCs' innate therapeutic abilities to develop improved cellular therapies. The research shows particular promise in conditions involving prolonged or exaggerated inflammation, where MSCs have demonstrated significant efficacy in clinical trials. His scientific contributions span multiple disciplines including regenerative medicine, neurology, immunology, and trauma surgery. Dr. Olson has published extensively on MSC therapies, with recent work expanding into synthetic biology approaches and novel drug delivery systems. His collaborative research extends across multiple institutions and specialties, reflecting the interdisciplinary nature of modern regenerative medicine research. Dr. Olson's laboratory focuses on three primary research directions: Comparing different MSC and MSC-like cell preparations to identify optimal therapeutic candidates Studying MSC interactions with specific immune cell populations, particularly their influence on monocyte and macrophage phenotype Developing mixed cell preparations using selectively permeable scaffolds for implantable therapeutic constructs His work aims to translate basic MSC research into clinical applications, with a particular emphasis on improving treatments for Traumatic Brain Injury through better understanding of MSC mechanisms and therapeutic potential.
Dr. Nicolas Lehrbach is an Assistant Professor in the Basic Sciences Division at Fred Hutchinson Cancer Center. His research focuses on cellular protein degradation pathways, particularly proteasome regulation, and their roles in aging, cancer, neurodegenerative diseases, and rare genetic disorders like NGLY1 deficiency. He leads the Lehrbach Lab, which employs C. elegans as a primary model organism for genetic screens and molecular analyses. Education: PhD, University of Cambridge (2010) MPhil, Developmental Biology, University of Cambridge (2006) BSc (Hons), University of Sydney (2004) Research Focus: Dr. Lehrbach investigates how cells regulate protein degradation via the proteasome and the SKN-1A/Nrf1 transcription factor. His work aims to uncover mechanisms that could lead to therapies for conditions where proteasome dysfunction occurs, such as neurodegeneration or cancer resistance. Key areas include: Dynamic control of proteasome activity in health and disease Genetic compensation pathways in NGLY1 deficiency Proteasome inhibitor resistance in cancer Aging and protein homeostasis collapse Publications: His 15 most recent articles (2013–2025) emphasize proteasome regulation, SKN-1A/Nrf1 signaling, and C. elegans genetics. Trends include molecular analyses of protein degradation, stress response pathways, and genetic screens for disease mechanisms. Awards: No scientific awards are mentioned in the provided text. Lab & Team: The Lehrbach Lab develops C. elegans reporters for high-throughput screens to identify novel regulators of protein degradation. Current projects explore therapeutic strategies for proteasome-related disorders.
Meng-Chao Yao is an Academician of Academia Sinica, Taiwan, and Research Fellow at the Institute of Molecular Biology (IMB), Academia Sinica. He leads a laboratory investigating molecular processes affecting genome stability in eukaryotes using Tetrahymena thermophila as a primary model organism. His research centers on Genome Instability and RNA Interference , with key discoveries including cis-acting sequences regulating chromosome breakage (15 bp), DNA deletion boundaries, and ribosomal gene amplification. His lab demonstrated that DNA deletion constitutes an ultimate RNAi-mediated gene silencing mechanism involving 27nt siRNA, H3K9/H3K27 tri-methylation, and domesticated transposase activity. Scientific awards: Academician of Academia Sinica No information on student advising or research grants is provided in the source text. His laboratory developed a genome-wide detection method for inverted repeats in human cancer progression, extending Tetrahymena-based gene amplification mechanisms to mammalian systems.
Dr. Wassana Yantasee is a Research Professor at Oregon Health & Science University (OHSU) specializing in nanomedicine and cancer immunotherapy. She founded PDX Pharmaceuticals in 2010 to translate her patented nanoparticle platform into clinical applications, securing over $13 million in funding for preclinical and IND studies through OHSU collaborations. Her research focuses on developing multifunctional nanoparticles for co-delivering siRNA, small molecules, antibodies, and antigens to combat cancer and infectious diseases. Key innovations include immune-modulating therapeutics that enhance antitumor responses while overcoming immunosuppression. She has served on approximately 40 NIH scientific review panels and mentors graduate students and postdoctoral researchers, many of whom have advanced to prestigious academic and medical institutions. Analysis of her 15 most recent publications reveals a dominant focus on breast and lung cancer immunotherapy using nanoparticle platforms. Her work consistently integrates siRNA delivery with conventional therapeutics (e.g., taxanes), targets immune checkpoints (PD-L1), and addresses drug resistance mechanisms. The research spans fundamental nanocarrier engineering to preclinical validation, with strong translational emphasis. Ronald L. Brodzinski Early Career Scientific Achievement Award (2007, PNNL) Council of Outstanding Early Career Engineers (2014, OSU) Dr. Yantasee's laboratory has secured significant grant funding through PDX Pharmaceuticals and OHSU partnerships, supporting preclinical development of lead drug candidates. Her nanoparticle platform demonstrates versatility across therapeutic modalities, including radiation sensitization and heavy metal detoxification. She maintains active collaborations with OHSU's cancer research teams, notably with Dr. Joe W. Gray.
